Rui-Chao Chai

List of Publications by Year
in descending order

37 papers	1,861 citations	361296 20 h-index	414303 32 g-index
40 all docs	40 docs citations	40 times ranked	1628 citing authors

#	Article	IF	Citations
1	Recurrent PTPRZ1â€MET fusion and a high occurrence rate of MET exon 14 skipping in brain metastases. Cancer Science, 2022, 113, 796-801.	1.7	7
2	Clinical practice guidelines for the management of adult diffuse gliomas. Cancer Letters, 2021, 499, 60-72.	3.2	194
3	A comprehensive model including preoperative peripheral blood inflammatory markers for prediction of the prognosis of diffuse spinal cord astrocytoma following surgery. European Spine Journal, 2021, 30, 2857-2866.	1.0	7
4	Chinese Glioma Genome Atlas (CGGA): A Comprehensive Resource with Functional Genomic Data from Chinese Glioma Patients. Genomics, Proteomics and Bioinformatics, 2021, 19, 1-12.	3.0	439
5	A potentially effective drug for patients with recurrent glioma: sermorelin. Annals of Translational Medicine, 2021, 9, 406-406.	0.7	1
6	Spinal Cord Diffuse Midline Gliomas With H3 K27m-Mutant: Clinicopathological Features and Prognosis. Neurosurgery, 2021, 89, 300-307.	0.6	18
7	METTL3 enhances the stability of MALAT1 with the assistance of HuR via m6A modification and activates NF-Î°B to promote the malignant progression of IDH-wildtype glioma. Cancer Letters, 2021, 511, 36-46.	3.2	86
8	YTHDF2 facilitates UBXN1 mRNA decay by recognizing METTL3-mediated m6A modification to activate NF-Î°B and promote the malignant progression of glioma. Journal of Hematology and Oncology, 2021, 14, 109.	6.9	92
9	Predictive value of MGMT promoter methylation on the survival of TMZ treated <i>IDH</i>-mutant glioblastoma. Cancer Biology and Medicine, 2021, 18, 271-282.	1.4	31
10	Molecular Characterization and Clinical Relevance of ANXA1 in Gliomas via 1,018 Chinese Cohort Patients. Frontiers in Cell and Developmental Biology, 2021, 9, 777182.	1.8	6
11	Characterization and prognostic significance of alternative splicing events in lowerâ€grade diffuse gliomas. Journal of Cellular and Molecular Medicine, 2020, 24, 13171-13180.	1.6	4
12	Transcriptional Characteristics of IDH-Wild Type Glioma Subgroups Highlight the Biological Processes Underlying Heterogeneity of IDH-Wild Type WHO Grade IV Gliomas. Frontiers in Cell and Developmental Biology, 2020, 8, 580464.	1.8	8
13	Clinicopathological characteristics and survival of spinal cord astrocytomas. Cancer Medicine, 2020, 9, 6996-7006.	1.3	18
14	ABCC8 mRNA expression is an independent prognostic factor for glioma and can predict chemosensitivity. Scientific Reports, 2020, 10, 12682.	1.6	14
15	Molecular subtyping reveals immune alterations in <scp><i>IDH</i></scp> wildâ€type lowerâ€grade diffuse glioma. Journal of Pathology, 2020, 251, 272-283.	2.1	42
16	Classification of diffuse lowerâ€grade glioma based on immunological profiling. Molecular Oncology, 2020, 14, 2081-2095.	2.1	48
17	The molecular characteristics of spinal cord gliomas with or without H3 K27M mutation. Acta Neuropathologica Communications, 2020, 8, 40.	2.4	51
18	Combinations of four or more CpGs methylation present equivalent predictive value for MGMT expression and temozolomide therapeutic prognosis in gliomas. CNS Neuroscience and Therapeutics, 2019, 25, 314-322.	1.9	42

#	Article	IF	Citations
19	A Novel DNA Methylation-Based Signature Can Predict the Responses of MGMT Promoter Unmethylated Glioblastomas to Temozolomide. Frontiers in Genetics, 2019, 10, 910.	1.1	22
20	Prognostic power of a lipid metabolism gene panel for diffuse gliomas. Journal of Cellular and Molecular Medicine, 2019, 23, 7741-7748.	1.6	59
21	Hypoxia induced LBH overexpression accelerates malignant progression in glioma. EBioMedicine, 2019, 49, 4-5.	2.7	1
22	Systematically profiling the expression of eIF3 subunits in glioma reveals the expression of eIF3i has prognostic value in IDH-mutant lower grade glioma. Cancer Cell International, 2019, 19, 155.	1.8	27
23	Systematically characterize the clinical and biological significances of 1p19q genes in 1p/19q non-codeletion glioma. Carcinogenesis, 2019, 40, 1229-1239.	1.3	60
24	m6A RNA methylation regulators contribute to malignant progression and have clinical prognostic impact in gliomas. Aging, 2019, 11, 1204-1225.	1.4	209
25	Molecular classification of IDH-mutant glioblastomas based on gene expression profiles. Carcinogenesis, 2019, 40, 853-860.	1.3	37
26	Gene Expression Profiling Stratifies IDH-Wildtype Glioblastoma With Distinct Prognoses. Frontiers in Oncology, 2019, 9, 1433.	1.3	16
27	Amino acid metabolismâ€related gene expressionâ€based risk signature can better predict overall survival for glioma. Cancer Science, 2019, 110, 321-333.	1.7	39
28	ADAMTSL4, a Secreted Glycoprotein, Is a Novel Immune-Related Biomarker for Primary Glioblastoma Multiforme. Disease Markers, 2019, 2019, 1-12.	0.6	66
29	A novel analytical model of MGMT methylation pyrosequencing offers improved predictive performance in patients with gliomas. Modern Pathology, 2019, 32, 4-15.	2.9	41
30	RNA processing genes characterize RNA splicing and further stratify lower-grade glioma. JCI Insight, 2019, 5, .	2.3	20
31	A novel gene signature based on five glioblastoma stem-like cell relevant genes predicts the survival of primary glioblastoma. Journal of Cancer Research and Clinical Oncology, 2018, 144, 439-447.	1.2	36
32	PATH-60. BIOINFORMATIC PROFILING IDENTIFIES THE SECRETED GLYCOPROTEIN ADAMTSL4 TO BE A POTENTIAL NOVEL IMMUNE-RELATED BIOMARKER FOR PRIMARY GLIOBLASTOMA. Neuro-Oncology, 2018, 20, vi171-vi172.	0.6	0
33	PATH-61. A NOVEL ANALYSIS MODEL OF MGMT METHYLATION PYROSEQUENCING OFFERS AN OPTIMAL PREDICTIVE PERFORMANCE IN GLIOMAS. Neuro-Oncology, 2018, 20, vi172-vi172.	0.6	0
34	Expression profile analysis of antisense long non-coding RNA identifies WDFY3-AS2 as a prognostic biomarker in diffuse glioma. Cancer Cell International, 2018, 18, 107.	1.8	33
35	Identification of an energy metabolism-related signature associated with clinical prognosis in diffuse glioma. Aging, 2018, 10, 3185-3209.	1.4	72
36	1p19q Gene Transcription Profiles Closely Correlated to Malignancy and Prognosis of 1p/19q Non-Codeletion Gliomas. SSRN Electronic Journal, 0, , .	0.4	0

#	Article	IF	Citations
37	Systematic Profiling of Alternative Splicing in Lower-Grade Diffuse Gliomas. SSRN Electronic Journal, 0, , .	0.4	0